文献速递白血病

Ziftomenib联合维奈克拉和阿扎胞苷治疗复发/难治性NPM1突变急性髓系白血病

Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.
PubMed 文献 · Blood · 2026-01-01

KOMET-007 1期试验评估了ziftomenib联合维奈克拉/阿扎胞苷在复发/难治性NPM1突变急性髓系白血病中的疗效与耐受性。67例患者中,600mg组复合完全缓解率为46%,MRD阴性率67%,中位缓解持续时间8.6个月,中位总生存未达到。联合方案耐受良好,在维奈克拉初治患者中缓解率更高。

要点

  • 600mg ziftomenib联合方案CRc率46%,MRD阴性率67%
  • 维奈克拉初治患者CRc率70%,经治患者仅24%
  • 常见≥3级不良事件为白细胞减少34%、血小板减少28%

核心结论

  • Ziftomenib 600mg联合维奈克拉/阿扎胞苷在复发/难治性NPM1突变AML中耐受良好,具有深度且持久的临床活性。

研究设计与样本

  • KOMET-007 1期试验,1a期剂量递增(200/400/600mg),1b期600mg扩展,共67例复发/难治性NPM1突变AML成人患者。

主要发现

  • 600mg组复合完全缓解率为46%(22/48),其中67%(12/18)达到中心MRD阴性(<0.01%阈值)。
  • 维奈克拉初治患者CRc率70%(16/23),维奈克拉经治患者CRc率24%(6/25)。
  • 维奈克拉初治和经治患者MRD阴性率分别为75%(9/12)和50%(3/6)。
  • 中位缓解持续时间8.6个月,中位总生存未达到。
  • 常见≥3级治疗中出现的不良事件:白细胞减少34%、血小板减少28%、发热性中性粒细胞减少和中性粒细胞减少各25%。

关键数值与推荐

  • 600mg ziftomenib联合标准剂量维奈克拉/阿扎胞苷为扩展期选定方案。
  • 复合完全缓解率46%,MRD阴性率67%(<0.01%阈值),中位缓解持续时间8.6个月。

临床怎么用

  • 对于复发/难治性NPM1突变AML,尤其维奈克拉初治患者,可考虑ziftomenib 600mg联合维奈克拉/阿扎胞苷。
  • 治疗期间需监测血细胞减少、发热性中性粒细胞减少、QT间期延长和分化综合征。

局限性

  • 1期试验样本量有限,缺乏随机对照。
  • 维奈克拉经治患者亚组缓解率较低,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ziftomenib, a potent, selective, oral menin inhibitor, is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard therapies for R/R and newly diagnosed AML. Here, we report the outcomes of adults with R/R NPM1-m AML treated with ziftomenib plus venetoclax/azacitidine. In phase 1a, patients received ziftomenib 200, 400, or 600 mg once daily with standard doses of venetoclax/azacitidine. In phase 1b, ziftomenib 600 mg was selected for expansion. A total of 67 patients were treated (27 phase 1a; 40 phase 1b). Median age was 66 years; 55% were male. Median number of previous therapies was 1 (range, 1-8); 55% received previous venetoclax, and 22% had received previous transplantation. Most common (≥20%) grade ≥3 treatment-emergent adverse events were leukopenia (34%), thrombocytopenia (28%), febrile neutropenia and neutropenia (25% each). Six patients developed corrected QT prolongation (1 ziftomenib-related; grade 1), and 2 experienced differentiation syndrome (grade 3); all events were successfully managed. In patients receiving ziftomenib 600 mg, composite complete remission (CRc) rate was 46% (22/48), with 67% (12/18) achieving central measurable residual disease (MRD) negativity (<0.01% threshold). In venetoclax-naïve and -exposed patients, CRc rates were 70% (16/23) and 24% (6/25), with MRD negativity rates of 75% (9/12) and 50% (3/6), respectively. Median duration of response was 8.6 months, and median overall survival was not reached. The combination of ziftomenib 600 mg with venetoclax/azacitidine was well tolerated with deep and durable clinical activity in R/R NPM1-m AML. This trial was registered at www.clinicaltrials.gov as NCT05735184.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang ES, Erba H, Zeidan AM, et al. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026. PMID: 42227701. doi:10.1182/blood.2026034043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。